drugset / Trial / NCT01882400

Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy

NCT01882400

Phase 4 Completed 11 enrolled Gilles Boire Procter and Gamble · collab
NaSingle-groupOpen-labelPrevention

Summary

By supplying an adequate amount of calcium and vitamin D with the addition of weekly bisphosphonate, the investigators will be able to increase bone mass and decrease the incidence of fragility fractures in these children with muscular dystrophy. The investigators think this treatment will also decrease the intensity of pain frequently present in these patients and slow the progression of scoliosis.

Timeline

Start
2001-05
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule Oral
Subject Risedronate Small molecule Oral
Background Calcium carbonate Other / unclassified
Background Vitamin D Other / unclassified